Dr. Brady Stein is an Assistant Professor, in the Department of Medicine, Hematology/Oncology Division, at the Northwestern Feinberg School of Medicine in Chicago, Illinois. Dr. Stein is interested in the clinical investigation and clinical epidemiology of the classical myeloproliferative neoplasms. He conducts clinical trials for patients with MPNs, and has collaborated with laboratory investigators, evaluating new druggable targets in the MPN. One such collaboration with Dr. Crispino has led to an investigator initiated clinical trial of Alisertib, an Aurora kinase A inhibitor, for patients with myelofibrosis. Dr. Stein has received a grant to study immunotherapy in myelofibrosis. Dr. Stein serves as the scientific co-chair for a multi-institutional study of the epidemiology of PV. Finally, Dr. Stein is a panelist on the NCCN guidelines for MPNS. Dr. Stein discloses that he has received funding from Incyte Corporation for his work as a consultant for the company.